Intellect Neurosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic agents for the treatment and prevention of neurodegenerative conditions primrily proteinopathies. Its licensed programs include OX1 (SHP622), an orally-administered, brain-penetrating, and naturally-occurring copper-binding small molecule, which has tested in human Phase I safety clinical trials for the treatment of various neurodegenerative diseases, such as Friedreich’s Ataxia. The company’s internal pipeline, which are in preclincial comprise TauC3 for the treatment of Alzheimer’s disease; and CONJUMAB-A for the treatment of age related macular degeneration. The company has a research collaboration agreement with Medical Research Council Technology, as well as license agreements with the South Alabama Medical Science Foundation, New York University, AHP Manufacturing BV, and Northwestern University. Intellect Neurosciences, Inc. was founded in 2005 and is based in Englewood Cliffs, New Jersey.